Draft Field Note / 2026-07-26

Approval Is Not Exposure: A Draft Across the Boundary

A cross-disciplinary medical-policy assertion, an audio debate, and an open request for disciplined feedback.

Audio Debate / 23 minutes

FDA approval versus biological safety.

The debate starts where the draft starts: approval and accumulated human exposure are both evidence, but they are not evidence of the same thing.

I am preparing to make a cross-disciplinary assertion into medical policy. That sentence should make a person slow down. I am not a regulator or a physician, and I am not trying to become one by vocabulary. I am trying to take a distinction that is visible in the evidence, keep it inside its lawful limits, and ask whether current consent language sometimes collapses two different kinds of knowledge into one category.

The draft is called Approval Is Not Exposure. FDA approval establishes that a particular product met an applicable benefit-risk and quality standard for a defined use, population, dose, route, and evidence package. Accumulated human exposure establishes something else: how much opportunity common, rare, delayed, interaction-dependent, and population-specific effects have had to become visible over time.

I am deliberately trying not to describe the paper in Nested Causal Modelling terms. The method is underneath it, but the medical-policy claim should survive in ordinary evidentiary language. If it cannot, the claim is not ready to cross disciplines.

Draft-process archive: this field note and its feedback form preserve the public working stage. The revised paper is now a DOI publication; neither version is medical advice, a therapeutic recommendation, or a claim that historical use proves efficacy or safety.